Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $51,034.75 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 533 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $95.75, for a total value of $51,034.75. Following the transaction, the senior vice president directly owned 14,219 shares in the company, valued at $1,361,469.25. This represents a 3.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total value of $53,597.60.
• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total value of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00.
• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The shares were sold at an average price of $84.63, for a total transaction of $846,215.37.

Oruka Therapeutics Trading Down 4.9%

NASDAQ:ORKA opened at $89.93 on Thursday. Oruka Therapeutics, Inc. has a twelve month low of $14.89 and a twelve month high of $115.51. The company has a market cap of $5.95 billion, a PE ratio of -44.30 and a beta of -0.34. The company’s 50 day moving average is $96.79 and its two-hundred day moving average is $75.32.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, analysts expect that Oruka Therapeutics, Inc. will post -2.42 EPS for the current fiscal year.

Oruka Therapeutics News Roundup

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: ORKA-001 produced deeper and more durable responses in the ongoing Phase 2a EVERLAST-A trial. At Week 28, the PASI 100 response rate increased to 71.4% and PASI 90 reached 87.3%, even though patients received no additional dosing after Week 4. Patients who initially received placebo and later crossed over achieved response rates comparable to those initially treated with ORKA-001. Oruka Therapeutics Week 28 Data
• Positive Sentiment: The company reported that ORKA-001 maintained a favorable safety and tolerability profile through Week 28. Investors are now awaiting 52-week EVERLAST-A results, expected in December 2026, and Week 16 EVERLAST-B data, expected in the fourth quarter of 2026. Positive EVERLAST-A Results
• Neutral Sentiment: Analyst sentiment remains broadly supportive, with a reported average price target of $133 and a “Moderate Buy” consensus. However, the stock’s elevated valuation and clinical-stage status leave it sensitive to changes in expectations and trial-data interpretation.
• Negative Sentiment: Shares fell even after the positive update, indicating that the results did not generate enough near-term buying interest to overcome selling pressure. Several reports specifically highlighted the decline following the Week 28 data release. Oruka Shares Fall Despite Week 28 Responses
• Negative Sentiment: Oruka disclosed additional insider selling: Senior Vice President Arjun Agarwal sold 533 shares for approximately $51,035 under a pre-arranged Rule 10b5-1 plan. The sale was relatively small compared with his remaining holdings, but it follows several earlier sales and may weigh on sentiment. Oruka Insider Sale

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ORKA. BlackRock Inc. acquired a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $474,916,000. Jupiter Topco LLC purchased a new stake in shares of Oruka Therapeutics during the second quarter worth about $130,968,000. Bank of America Corp DE acquired a new position in shares of Oruka Therapeutics during the second quarter valued at approximately $33,578,000. Braidwell LP purchased a new position in Oruka Therapeutics in the 2nd quarter valued at $26,473,000. Finally, Atika Capital Management LLC purchased a new stake in shares of Oruka Therapeutics in the first quarter valued at approximately $11,277,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Mizuho set a $120.00 target price on Oruka Therapeutics in a report on Thursday, September 3rd. Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Guggenheim reiterated a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. BTIG Research reissued a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $133.00.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.